Published in Medical Letter on the CDC and FDA, February 12th, 2006
According to a study from the United States, "In June 2003, the U.S. Food and Drug Administration licensed a trivalent live, attenuated influenza vaccine (LAIV-T) for intranasal administration to healthy persons 5 to 49 years of age. Although prelicensure testing involved 20,228 vaccinees, clinical trials were not of sufficient size to detect rare adverse events reliably."
"[Our] objective was to identify adverse events reported following LAIV-T administration after licensure using all adverse events reported to the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA